Business
Natera Presents New Data at the 2020 SITC Annual Meeting Highlighting Applications of Personalized ctDNA Testing in Immunotherapy Treatment Monitoring
Clinical case studies demonstrate the performance of the Signatera™ test in cancer patients receiving immunotherapy SAN CARLOS, Calif., Nov. 10, 2020
About this update from Natera, Inc.
[{"type":"text","content":"Clinical case studies demonstrate the performance of the Signatera™ test in cancer patients receiving immunotherapy\n\n\nSAN CARLOS, Calif., Nov. 10, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new immunotherapy data on its personalized and tumor-informed molecular residual disease (MRD) assay, Signatera, at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting, taking place November 9-14, 2020. \n\n \n \n \n \n \n \n\n \nNatera will present four posters demonstrating the ability of Signatera to monitor response to immunotherapy in colorectal and breast cancer.\n\"Tumor-informed circulating tumor DNA tests have broad clinical utility across cancer types,\" said Georges Azzi, MD, oncologist at Holy Cross Health in Ft. Lauderdale, Florida and co-author of one of the posters presented. \"I am excited to partner with Natera to further explore early indications of treatment response, or lack thereof, using this novel technology.\"\n\"We have consistently demonstrated the clinical utility of MRD testing with Signatera to help patients detect recurrence earlier, and we are now seeing evidence of Signatera's ability to effectively monitor immunotherapy treatment,\" said Alexey Aleshin, MD, Natera's Senior Medical Director of Oncology. \"The studies we are presenting at SITC showcase Signatera's broadened capability to evaluate immunotherapy treatment response, an area in which there is a significant unmet need for more optimal diagnostic tools.\"\nDetails about the abstracts are as follows:\nAbstract #23 | Poster PresentationPresenter: Pashtoon Kasi, MD, MS\nCirculating tumor DNA (ctDNA) serial analysis during progression on PD-1 blockade and later CTLA-4 rescue in patients with mismatch repair deficient metastatic colorectal cancer\nA case series of three patients with mismatch repair deficient (dMMR), high microsatellite instability metastatic colorectal cancer (CRC), who progressed on PD-1 inhibitor pembrolizumab and were being treated with CTLA-4 inhibitors (nivolumab and ipilimumab). All patients were monitored with radiological imaging and serial ctDNA assessments using Signatera. ctDNA levels were corroborated by imaging in all cases and predicted tumor responses weeks ahead of imaging, supporting the use of ctDNA ...